Table 3.

Summary of cardiovascular irAEs

Case	Cardiovascular complications	Age (years), sex	Malignancy	ICI	Days from first ICI administration to cardiovascular irAEs	Days from non-cardiovascular irAEs to cardiovascular irAEs	Management	Outcome
1	Paf	66, M	Renal cancer	Nivolumab	64	15	Pilsicainide	Survived
2	Paf	71, M	NSCLC	Pembrolizumab	35	25	Anticoagulant therapy	Survived
3	AFL	44, F	NSCLC	Nivolumab	4	(-)	Bisoprolol	Cancer death
4	PSVT	72, F	NSCLC	Nivolumab	89	65	Bisoprolol	Cancer death
5	VT	71, M	Melanoma	Pembrolizumab	6	(-)	Catheter ablation	Survived
6	AP	74, M	NSCLC	Nivolumab	201	(-)	PCI	Survived
7	AP	79, M	NSCLC	Nivolumab	1102	986	Nitrous acid	Survived
8	VSP	58, M	Melanoma	Pembrolizumab	294	204	Nitrous acid	Survived
9	Pericardial effusion	45, M	NSCLC	Pembrolizumab	59	58	Pericardial drainage	Cancer death
10	Pericardial effusion	45, M	NSCLC	Pembrolizumab	253	246	Pericardial drainage	Cancer death
11	PE	77, F	NSCLC	Pembrolizumab	161	(-)	Anticoagulant therapy	Survived
12	HF	71, M	NSCLC	Nivolumab	72	(-)	Diuretics	Cancer death
13	Fulminant myocarditis	59, M	Melanoma	Ipilimumab  →  Nivolumab	495	418	MCS + PSL pulse	Survived from myocarditis, Cancer death
14	Myocardial vasculitis	79, F	Melanoma	Pembrolizumab	263	74	PSL	Survived

ICI immune checkpoint inhibitor, Paf paroxysmal atrial fibrillation, AFL atrial flutter, PSVT paroxysmal supraventricular tachycardia, VT ventricular tachycardia, AP angina pectoris, VSP vasospastic angina, PE pulmonary embolism, HF heart failure, NSCLC non-small cell lung cancer, PCI percutaneous coronary intervention, MCS mechanical circulatory support, PSL prednisolone, Other abbreviations as in Table 1